Inflammatory biomarkers for prediction of tumor responses and adverse events in non-small cell lung cancer patients treated with anti-PD-1 inhibitor.

e21050Background: Although programmed death (PD)-1 immune checkpoint inhibitors have been shown to elicit durable responses and prolong survival in patients with non-small cell lung cancer (NSCLC),...